Bausch + Lomb was valued at $6.48 billion in the company’s U.S. market debut on May 6 as the eye-care company’s shares opened nearly 3 percent above an offer price that was well below the targeted range.
The U.S. Securities and Exchange Commission (SEC) added 12 China companies to their delisting watchlist.
Organon on June 3 celebrated the launch of the global women’s health company with employees and women from around the world, as the Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE.
An outbreak of coronavirus in New York could cause more sharp selling of stocks, but markets would likely continue to function even if the floor of the New York Stock Exchange had to close.
Novartis will officially spin its Alcon eye-care business off into a separately traded standalone business unit on April 9, 2019.
The biotech industry did OK in July 2017. The NYSE ARCA Biotech Index and the iShares NASDAQ Biotechnology Index (ETF) grew about 1.9 percent and 2.9 percent, respectively last month. There have been 26 new molecular entity approvals so far this year. With that figure in mind, here are eight companies looking at PDUFA dates in August 2017.
Mallinckrodt Plc, one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said.
St. Jude Medical Inc. filed a lawsuit against short-selling firm Muddy Waters and cyber security company MedSec Holdings Ltd.
